Study on the Effects of Angiotensin Receptor/Neprilysin Inhibitors on Renal Haemodynamics in Healthy Dogs
- PMID: 38892356
- PMCID: PMC11172652
- DOI: 10.3390/ijms25116169
Study on the Effects of Angiotensin Receptor/Neprilysin Inhibitors on Renal Haemodynamics in Healthy Dogs
Abstract
An angiotensin receptor/neprilysin inhibitor (ARNI), a heart failure treatment, is a combination drug made up of sacubitril, a neprilysin inhibitor, and valsartan, a vascular receptor blocker. No human or veterinary studies regarding the effect of ARNI on renal haemodynamics in the absence of cardiac or renal issues exist. Therefore, we investigated the effect of ARNI on renal haemodynamics in five healthy dogs. ARNI was administered to all five dogs at an oral dose of 20 mg/kg twice daily for 4 weeks. Renal haemodynamics were assessed on the day before ARNI administration (BL), on Day 7, and on Day 28. The glomerular filtration rate (GFR) significantly increased on Day 28 compared to BL and Day 7, whereas renal plasma flow increased on Day 7 and Day 28 compared to BL. Systolic blood pressure significantly decreased between BL and Day 28. Plasma atrial natriuretic peptide (ANP) concentrations increased on Day 7 compared to BL. Additionally, ANP concentrations increased on Day 28 in three of the five dogs. Different ANP concentrations were observed in the remaining two dogs. Both urine output volume and heart rate remained relatively stable and did not exhibit significant change. In conclusion, ARNI may enhance renal haemodynamics in healthy dogs. ARNI could be a valuable drug for treating both heart and kidney disease in dogs.
Keywords: angiotensin receptor/neprilysin inhibitor; glomerular filtration rate; renal haemodynamics; renal plasma flow.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11172652/bin/ijms-25-06169-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11172652/bin/ijms-25-06169-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11172652/bin/ijms-25-06169-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11172652/bin/ijms-25-06169-g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11172652/bin/ijms-25-06169-g005.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11172652/bin/ijms-25-06169-g006.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11172652/bin/ijms-25-06169-g007.gif)
Similar articles
-
Effects of Angiotensin Receptor-Neprilysin Inhibitor in Arrhythmogenicity Following Left Atrial Appendage Closure in an Animal Model.Cardiovasc Drugs Ther. 2021 Aug;35(4):759-768. doi: 10.1007/s10557-021-07174-2. Epub 2021 Apr 5. Cardiovasc Drugs Ther. 2021. PMID: 33818689
-
Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.J Hypertens. 2020 Apr;38(4):755-764. doi: 10.1097/HJH.0000000000002326. J Hypertens. 2020. PMID: 31790054
-
Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure.BMC Pharmacol Toxicol. 2019 May 3;20(1):23. doi: 10.1186/s40360-019-0304-z. BMC Pharmacol Toxicol. 2019. PMID: 31053170 Free PMC article.
-
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.Circulation. 2016 Mar 15;133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622. Circulation. 2016. PMID: 26976916 Free PMC article. Review.
-
Impact of Sacubitril-Valsartan on Markers of Glomerular Function.Curr Heart Fail Rep. 2020 Aug;17(4):145-152. doi: 10.1007/s11897-020-00463-1. Curr Heart Fail Rep. 2020. PMID: 32488503 Review.
References
-
- Yasue H., Yoshimura M., Sumida H., Kikuta K., Kugiyama K., Jougasaki M., Ogawa H., Okumura K., Mukoyama M., Nakao K. Localization and Mechanism of Secretion of B-Type Natriuretic Peptide in Comparison with Those of A-Type Natriuretic Peptide in Normal Subjects and Patients with Heart Failure. Circulation. 1994;90:195–203. doi: 10.1161/01.CIR.90.1.195. - DOI - PubMed
-
- Mazzetti S., Scifo C., Abete R., Margonato D., Chioffim M., Rossi J., Pisani M., Passafaro G., Grillo M., Poggio D., et al. Short-term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan. ESC Heart Fail. 2020;7:964–972. doi: 10.1002/ehf2.12656. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources